256 related articles for article (PubMed ID: 25980013)
1. Platelet-activating factor receptor contributes to antileishmanial function of miltefosine.
Gangalum PR; de Castro W; Vieira LQ; Dey R; Rivas L; Singh S; Majumdar S; Saha B
J Immunol; 2015 Jun; 194(12):5961-7. PubMed ID: 25980013
[TBL] [Abstract][Full Text] [Related]
2. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response.
Wadhone P; Maiti M; Agarwal R; Kamat V; Martin S; Saha B
J Immunol; 2009 Jun; 182(11):7146-54. PubMed ID: 19454711
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
Gupta R; Kushawaha PK; Samant M; Jaiswal AK; Baharia RK; Dube A
J Antimicrob Chemother; 2012 Feb; 67(2):440-3. PubMed ID: 22121191
[TBL] [Abstract][Full Text] [Related]
4. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms.
Murray HW; Delph-Etienne S
J Infect Dis; 2000 Feb; 181(2):795-9. PubMed ID: 10669380
[TBL] [Abstract][Full Text] [Related]
5. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
Sane SA; Shakya N; Haq W; Gupta S
J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
[TBL] [Abstract][Full Text] [Related]
6. Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro.
Das S; Rani M; Pandey K; Sahoo GC; Rabidas VN; Singh D; Das P
J Antimicrob Chemother; 2012 Oct; 67(10):2373-8. PubMed ID: 22761329
[TBL] [Abstract][Full Text] [Related]
7. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
Shakya N; Sane SA; Vishwakarma P; Bajpai P; Gupta S
Acta Trop; 2011 Aug; 119(2-3):188-93. PubMed ID: 21679679
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
[TBL] [Abstract][Full Text] [Related]
9. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
Tiwari B; Pahuja R; Kumar P; Rath SK; Gupta KC; Goyal N
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031196
[TBL] [Abstract][Full Text] [Related]
10. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
Croft SL; Engel J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
[TBL] [Abstract][Full Text] [Related]
11. Leptin augments protective immune responses in murine macrophages and enhances potential of miltefosine against experimental visceral leishmaniasis.
Shivahare R; Ali W; Vishwakarma P; Natu SM; Puri SK; Gupta S
Acta Trop; 2015 Oct; 150():35-41. PubMed ID: 26119043
[TBL] [Abstract][Full Text] [Related]
12. Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.
Deep DK; Singh R; Kulshrestha A; Wajid S; Salotra P
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297367
[TBL] [Abstract][Full Text] [Related]
13. Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death.
Mishra J; Singh S
Exp Parasitol; 2013 Oct; 135(2):397-406. PubMed ID: 23968687
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis.
Shakya N; Sane SA; Haq W; Gupta S
Parasitol Res; 2012 Aug; 111(2):563-70. PubMed ID: 22392136
[TBL] [Abstract][Full Text] [Related]
15. Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: role of TLR4 and TLR9.
Mukherjee AK; Gupta G; Adhikari A; Majumder S; Kar Mahapatra S; Bhattacharyya Majumdar S; Majumdar S
Int Immunopharmacol; 2012 Apr; 12(4):565-72. PubMed ID: 22361489
[TBL] [Abstract][Full Text] [Related]
16. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection.
Bimal S; Sinha S; Singh SK; Narayan S; Kumar V; Verma N; Ranjan A; Sinha PK; Das VN; Pandey K; Kar SK; Das P
Exp Parasitol; 2012 Jul; 131(3):274-82. PubMed ID: 22580024
[TBL] [Abstract][Full Text] [Related]
17. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
Escobar P; Yardley V; Croft SL
Antimicrob Agents Chemother; 2001 Jun; 45(6):1872-5. PubMed ID: 11353640
[TBL] [Abstract][Full Text] [Related]
18. Possible mechanism of miltefosine-mediated death of Leishmania donovani.
Verma NK; Dey CS
Antimicrob Agents Chemother; 2004 Aug; 48(8):3010-5. PubMed ID: 15273114
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
Gonzalez-Fajardo L; Fernández OL; McMahon-Pratt D; Saravia NG
PLoS Negl Trop Dis; 2015 May; 9(5):e0003820. PubMed ID: 26024228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]